Hostname: page-component-7bb8b95d7b-fmk2r Total loading time: 0 Render date: 2024-09-25T17:22:08.591Z Has data issue: false hasContentIssue false
  • English
  • Français

Surgical Resection and Glioblastoma: Molecular Profiling and Safety

Published online by Cambridge University Press:  02 December 2014

Rolando Del Maestro
Rolando Del Maestro*
Affiliation:
McGill University, Montreal, Quebec, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 5 , September 2012 , pp. 561 - 562
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Dea, N, Fournier-Gosselin, MP, Mathieu, D, Goffaux, P, Fortin, D.Does extent of resection impact survival in patients bearing glioblastoma? Can J Neurol Sci. 2012;39(5):632–7.Google Scholar
2.Mason, WP, Del Maestro, R, Eisenstat, D, et al.Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110–17.Google Scholar
3.Stupp, R, Mason, WP, van der Bent, MJet al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.Google Scholar
4.Hegi, ME, Diserens, AC, Gorlia, T, et al.MGMT gene silencing and benefit from temozolomide in glioblastioma. N eng J Med. 2005;352:997–1003.Google Scholar
5.Gilbert, MR, Wang, M, Aldape, D, et al.RTOG 0525; a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with dose-dense (DD) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011;29 (suppl; abstr 2006).CrossRefGoogle Scholar
6.Stupp, R, Hegi, M, Mason, WP, et al.effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5 year analysis of the eORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefGoogle Scholar
7.Hochberg, FH, Pruitt, A.Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–11.CrossRefGoogle ScholarPubMed
8.Brandes, AA, Tosoni, A, Franceschi, E, et al.Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27: 1275–9.CrossRefGoogle ScholarPubMed
9.Stummer, W, Meinel, T, Ewelt, C, et al.Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol. 2012; 108:89–97.CrossRefGoogle ScholarPubMed
10.Stummer, W, Nestler, U, Stockhammer, F, et al.favorable outcome in the elderly cohort treated by concomitant temozolomide radiotherapy in a multicentric phase II safety study of 5-AlA. J Neurooncol. 2011;103:361–70.CrossRefGoogle Scholar
11.Stummer, W, Tonn, J-C, Mehdorn, HM, et al.Counterbalancing risks and gains from extended resections in malignant gliomas surgery: a supplemental analysis from the randomized 5-aminolevulinic acid gliomas resection study. J Neurosurg. 2011; 114:613–23.Google Scholar
12.von Deimling, A, Korshunov, A, Hartmann, C.The next generation of glioma biomarkers: MGMT methylation, BRAf fusions and IDH1 mutations. Brain Path. 2011;21:74–87.CrossRefGoogle ScholarPubMed